Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/phpp.13018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Low-Dose UVA-1 Phototherapy Treatment for Hand Eczema: A Safety and Effective Treatment.
Photodermatol Photoimmunol Photomed
January 2025
Hospital Universitario Clínico San Cecilio, Granada, Spain.
Biological effects of a new ultraviolet A prototype based on light-emitting diodes on the treatment of localized scleroderma.
Exp Dermatol
December 2020
Department of Dermatology, University Medical Center Regensburg, Regensburg, Germany.
Ultraviolet A (UVA ) phototherapy (spectral range 340-400 nm) is a well-established treatment option for various skin diseases such as localized scleroderma. Recent improvements of conventional UVA light sources (metal-halide or fluorescent lamps) have brought attention to a new light-emitting diode (LED) technology with remarkable advantages in handling and clinical routine. This study provides a preclinical histological and molecular evaluation of an LED-based UVA prototype with a narrower spectral range (360-400 nm) for treating localized scleroderma.
View Article and Find Full Text PDFInterventions for morphea.
Cochrane Database Syst Rev
July 2019
Cochrane Brazil, Centro de Estudos de Saúde Baseada em Evidências e Avaliação Tecnológica em Saúde, Rua Borges Lagoa, 564 cj 63, São Paulo, São Paulo, Brazil, 04038-000.
Background: Morphea (morphoea) is an immune-mediated disease in which excess synthesis and deposition of collagen in the skin and underlying connective tissues results in hardened cutaneous areas. Morphea has different clinical features according to the subtype and stage of evolution of the disease. There is currently no consensus on optimal interventions for morphea.
View Article and Find Full Text PDF[Primary skin lymphomas: Current therapy].
Ann Dermatol Venereol
February 2019
Unité Inserm U1058, département de dermatologie, université Montpellier, hôpital Saint-Éloi, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France. Electronic address:
Therapeutic progress in primary cutaneous lymphomas continues to be largely dominated by the T-cell lymphomas, towards which the great majority of recent therapeutic innovations have been directed. The latter include local treatments consisting either of relatively classical but "revamped" approaches involving different pharmaceutical forms (example: chlormethine gel) or else lower but seemingly equally effective dosages (electron therapy), or of more innovative approaches (example: UVA-1, dynamic phototherapy, imiquimod, resimiquimod). However, significant progress has been made chiefly in terms of systemic treatments with the emergence of "targeted" drugs that directly and specifically target tumour cells (monoclonal antibodies directed against CD30, CCR4 or CD158k) and the further development of "small" molecules such as histone deacetylase inhibitors and new cytostatics.
View Article and Find Full Text PDFVitiligo in Children: What's New in Treatment?
Open Access Maced J Med Sci
January 2018
University G. Marconi of Rome, Dermatology and Venereology, Rome, Italy.
Vitiligo is an acquired chronic hypopigmentary disorder, which usually stars in childhood. The Authors discuss a short review of the more innovative therapies for childhood vitiligo.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!